Cargando…

Discovery of novel PDE9A inhibitors with antioxidant activities for treatment of Alzheimer’s disease

Phosphodiesterase-9 (PDE9) is a promising target for treatment of Alzheimer’s disease (AD). To discover multifunctional anti-AD agents with capability of PDE9 inhibition and antioxidant activity, a series of novel pyrazolopyrimidinone derivatives, coupling with the pharmacophore of antioxidants such...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Chen, Zhou, Qian, Wu, Xu-Nian, Huang, Ya-Dan, Zhou, Jie, Lai, Zengwei, Wu, Yinuo, Luo, Hai-Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011943/ https://www.ncbi.nlm.nih.gov/pubmed/29271265 http://dx.doi.org/10.1080/14756366.2017.1412315

Ejemplares similares

Structure-based discovery of orally efficient inhibitors via unique interactions with H-pocket of PDE8 for the treatment of vascular dementia
por: Wu, Xu-Nian, et al.
Publicado: (2022)

Structure-based design, synthesis, and biological evaluation of novel pyrimidinone derivatives as PDE9 inhibitors
por: Wu, Xu-Nian, et al.
Publicado: (2018)

Discovery of novel PDE9 inhibitors capable of inhibiting Aβ aggregation as potential candidates for the treatment of Alzheimer’s disease
por: Su, Tao, et al.
Publicado: (2016)

Structure-Based Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel PDE10 Inhibitors With Antioxidant Activities
por: Li, Jinxuan, et al.
Publicado: (2018)

Correction to: Zhang et al., Discovery of novel PDE9A inhibitors with antioxidant activities for treatment of Alzheimer’s disease
Publicado: (2018)

Design, Synthesis, and Evaluation of Dihydropyranopyrazole Derivatives as Novel PDE2 Inhibitors for the Treatment of Alzheimer’s Disease
por: Zhou, Yan, et al.
Publicado: (2021)

Computational Study on Selective PDE9 Inhibitors on PDE9-Mg/Mg, PDE9-Zn/Mg, and PDE9-Zn/Zn Systems
por: Sivakumar, Dakshinamurthy, et al.
Publicado: (2021)

Discovery of a Phosphodiesterase 9A Inhibitor as a Potential Hypoglycemic Agent
por: Shao, Yong-xian, et al.
Publicado: (2014)

Reversal of neurobehavioral social deficits in dystrophic mice using inhibitors of phosphodiesterases PDE5A and PDE9A
por: Alexander, M S, et al.
Publicado: (2016)

Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension
por: Yang, Yuncong, et al.
Publicado: (2020)

Discovery of novel phosphodiesterase-1 inhibitors for curing vascular dementia: Suppression of neuroinflammation by blocking NF-κB transcription regulation and activating cAMP/CREB axis
por: Zhou, Qian, et al.
Publicado: (2023)

Discovery of novel KRAS‒PDEδ inhibitors with potent activity in patient-derived human pancreatic tumor xenograft models
por: Chen, Long, et al.
Publicado: (2022)

Role of Phosphodiesterase 7 (PDE7) in T Cell Activity. Effects of Selective PDE7 Inhibitors and Dual PDE4/7 Inhibitors on T Cell Functions
por: Szczypka, Marianna
Publicado: (2020)

PDE9 Inhibitor PF-04447943 Attenuates DSS-Induced Colitis by Suppressing Oxidative Stress, Inflammation, and Regulating T-Cell Polarization
por: Rana, Mohammad Nasiruddin, et al.
Publicado: (2021)

Treating COPD with PDE 4 inhibitors
por: Brown, William M
Publicado: (2007)

Identification of pyrazolopyridazinones as PDEδ inhibitors
por: Papke, Björn, et al.
Publicado: (2016)

Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia
por: Layton, Mark E., et al.
Publicado: (2023)

Central serous chorioretinopathy treatment with a systemic PDE5 and PDE6 inhibitor (sildenafil)
por: Coleman, D. Jackson, et al.
Publicado: (2020)

Activation of PDE10 and PDE11
por: Jäger, Ronald, et al.
Publicado: (2011)

Pharmacophore Modeling and Virtual Screening for the Discovery of New type 4 cAMP Phosphodiesterase (PDE4) Inhibitors
por: Niu, Miaomiao, et al.
Publicado: (2013)

The efficacy of PDE5 inhibitors in diabetic patients
por: Swiecicka, Agnieszka
Publicado: (2022)

PDE5 inhibitor drugs for use in dementia
por: Hainsworth, Atticus H., et al.
Publicado: (2023)

Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development
por: Kayık, Gülru, et al.
Publicado: (2017)

A Yeast-Based Chemical Screen Identifies a PDE Inhibitor That Elevates Steroidogenesis in Mouse Leydig Cells via PDE8 and PDE4 Inhibition
por: Demirbas, Didem, et al.
Publicado: (2013)

BAY-7081: A Potent, Selective, and Orally Bioavailable Cyanopyridone-Based PDE9A Inhibitor
por: Meibom, Daniel, et al.
Publicado: (2022)

Comparison of the Pharmacological Profiles of Selective PDE4B and PDE4D Inhibitors in the Central Nervous System
por: Zhang, Chong, et al.
Publicado: (2017)

Phosphodiesterase 9 (PDE9) regulates bovine tracheal smooth muscle relaxation
por: TAJIMA, Tsuyoshi, et al.
Publicado: (2018)

Treatment Strategy for Non-Responders to PDE5 Inhibitors
por: Park, Nam Cheol, et al.
Publicado: (2013)

Phosphodiesterase (PDE)-4 Inhibitors and COPD Correlation with Cancer
por: Organtzis, John, et al.
Publicado: (2014)

AB041. Evolution of PDE5 inhibitors in Korea
por: Moon, Du Geon
Publicado: (2015)

PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]
por: Booth, Laurence, et al.
Publicado: (2017)

Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis
por: Yang, Xudan, et al.
Publicado: (2023)

S31. ENHANCEMENT OF SYNAPTIC PLASTICITY BY COMBINATION OF PDE2 AND PDE9 INHIBITION PRESUMABLY VIA PRE- AND POST-SYNAPTIC MECHANISMS
por: Rosenbrock, Holger, et al.
Publicado: (2020)

Fragment-Based Discovery of AF9 YEATS Domain Inhibitors
por: Liu, Yaqian, et al.
Publicado: (2022)

Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review
por: Blauvelt, Andrew, et al.
Publicado: (2023)

Modulation of oxazolone-induced hypersensitivity in mice by selective PDE inhibitors
por: Moodley, I., et al.
Publicado: (1995)

PDE5 Inhibitors as Potential Tools in the Treatment of Cystic Fibrosis
por: Noel, Sabrina, et al.
Publicado: (2012)

Using PDE5 inhibitors for the prevention and treatment of colorectal cancer
por: Browning, Darren D
Publicado: (2015)

Design and Microwave Assisted Synthesis of Coumarin Derivatives as PDE Inhibitors
por: Kumbar, Mahadev N., et al.
Publicado: (2016)

Comparative dissolution study on counterfeit medicines of PDE-5 inhibitors
por: Deconinck, E., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ef2004qe79rrldnbcuqgkdd7au